SEC 13F Intelligence

Managers / Q3 2019 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$320M
Q3 2019
Positions
19
Filings on Record
16
2019–present window
Filed
Nov 12, 2019
original filing

Summary

Frazier Management LLC reported $320M in U.S.-listed holdings across 19 positions for Q3 2019.

The portfolio is heavily concentrated: ANAB alone accounts for 25.3% of reported value.

Compared with Q2 2019, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+10.5%
vs prior filed quarter
Top-10 Concentration
+86.1%
share of reported value
Largest Position
+25.3%
Anaptysbio

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 76.9%Other: 23.1%
  • Common Stock · 76.9% · $246M
  • Other · 23.1% · $74M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MIRMMIRUM PHARMACEUTICALS INCNEW+3.57M3.57M+$36M$36M
SYNLOGIC INCTRIMMED−582.8K282.6K−$7M$647,000
TRANSLATE BIO INCADDED+500.0K2.18M+$377,000$22M
IOVAIOVANCE BIOTHERAPEUTICS INCTRIMMED−437.7K1.75M−$22M$32M
ANABANAPTYSBIO INCHELD+02.32M−$50M$81M
MILLENDO THERAPEUTICS INCHELD+01.40M−$6M$10M
GRITSTONE ONCOLOGY INCHELD+02.06M−$5M$18M
KRYSKRYSTAL BIOTECH INCHELD+0895.0K−$5M$31M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

19 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ANABANAPTYSBIO INChistory →COM25.34%$81M2.32M
2MIRMMIRUM PHARMACEUTICALS INChistory →COM11.22%$36M3.57M
3IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM9.96%$32M1.75M
4KRYSKRYSTAL BIOTECH INChistory →COM9.72%$31M895.0K
5COLLCOLLEGIUM PHARMACEUTICAL INChistory →COM6.77%$22M1.89M
6TRANSLATE BIO INCCOM6.76%$22M2.18M
7GRITSTONE ONCOLOGY INCCOM5.57%$18M2.06M
8ALLENA PHARMACEUTICALS INCCOM4.10%$13M3.33M
9APTINYX INCCOM3.48%$11M3.19M
10ALPINE IMMUNE SCIENCES INCCOM3.18%$10M2.57M
11MILLENDO THERAPEUTICS INCCOM3.10%$10M1.40M
12ITERUM THERAPEUTICS PLCSHS2.78%$9M1.54M
13NABRIVA THERAPEUTICS PLCSHS2.66%$9M4.26M
14ENTASIS THERAPEUTICS HLDGS ICOM2.52%$8M1.35M
15SIERRA ONCOLOGY INCCOM0.99%$3M8.11M
16CIDARA THERAPEUTICS INCCOM0.82%$3M1.31M
17KEZAR LIFE SCIENCES INCCOM0.48%$2M467.7K
18BELLICUM PHARMACEUTICALS INCCOM0.35%$1M1.05M
19SYNLOGIC INCCOM0.20%$647,000282.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.